Mahana Therapeutics, developer of prescription digital therapeutics designed to empower sufferers with persistent situations to stay fuller lives, has signed an settlement with the Shopper Well being division of Bayer, which is able to see its new digital therapeutics commercialised.
The partnership will carry collectively the experience Mahana has in digital therapeutic growth with Bayer’s intention to ship merchandise to assist individuals take larger management of their very own well being via the usage of digital options.
Earlier this yr Bayer introduced the launch of a brand new enterprise unit. The Shopper Well being division is targeted on bringing new digitally-enabled precision well being merchandise to market. The division is prioritising the event of merchandise that may allow individuals to make use of digital options to take management of their well being, and facilitate their capability to make knowledgeable selections based mostly on private insights and novel supply mechanisms.
David Evendon-Challis, head of R&D and chief scientific officer for the Shopper Well being division of Bayer, mentioned: “Digital therapeutics are an ideal addition to our portfolio of care and faucet into new tech-savvy customers searching for drug-free therapies in addition to assist eradicate gaps in care provision. We’re excited to companion with Mahana Therapeutics and enter the sector of digital therapeutics in client well being.”
The primary product from Mahana Therapeutics was Mahana IBS which gives cognitive remedy to adults with the situation. The product was the primary digital therapeutic to obtain FDA clearance for the therapy of IBS.
Simon Levy, CEO of Mahana, mentioned: “This historic partnership is among the many first main investments ever made by a worldwide life sciences firm into the rising market for digital therapeutics.
“By way of this settlement, we will additional develop the provision of our revolutionary prescription digital therapeutics for sufferers and their caregivers all over the world who search efficient therapy for persistent situations.”